全文获取类型
收费全文 | 143840篇 |
免费 | 14097篇 |
国内免费 | 8557篇 |
专业分类
耳鼻咽喉 | 1096篇 |
儿科学 | 1846篇 |
妇产科学 | 1582篇 |
基础医学 | 21512篇 |
口腔科学 | 2519篇 |
临床医学 | 17357篇 |
内科学 | 20153篇 |
皮肤病学 | 1582篇 |
神经病学 | 7014篇 |
特种医学 | 5021篇 |
外国民族医学 | 65篇 |
外科学 | 13761篇 |
综合类 | 23439篇 |
现状与发展 | 29篇 |
一般理论 | 12篇 |
预防医学 | 10116篇 |
眼科学 | 3472篇 |
药学 | 16597篇 |
121篇 | |
中国医学 | 7834篇 |
肿瘤学 | 11366篇 |
出版年
2024年 | 570篇 |
2023年 | 2234篇 |
2022年 | 5746篇 |
2021年 | 7268篇 |
2020年 | 5306篇 |
2019年 | 4740篇 |
2018年 | 4968篇 |
2017年 | 4558篇 |
2016年 | 4348篇 |
2015年 | 6328篇 |
2014年 | 7826篇 |
2013年 | 7600篇 |
2012年 | 10641篇 |
2011年 | 11284篇 |
2010年 | 7930篇 |
2009年 | 6407篇 |
2008年 | 7708篇 |
2007年 | 7746篇 |
2006年 | 7022篇 |
2005年 | 6359篇 |
2004年 | 4957篇 |
2003年 | 4829篇 |
2002年 | 4120篇 |
2001年 | 3426篇 |
2000年 | 2955篇 |
1999年 | 2628篇 |
1998年 | 1687篇 |
1997年 | 1820篇 |
1996年 | 1275篇 |
1995年 | 1212篇 |
1994年 | 1095篇 |
1993年 | 786篇 |
1992年 | 966篇 |
1991年 | 890篇 |
1990年 | 796篇 |
1989年 | 745篇 |
1988年 | 658篇 |
1987年 | 572篇 |
1986年 | 534篇 |
1985年 | 428篇 |
1984年 | 377篇 |
1983年 | 306篇 |
1982年 | 272篇 |
1981年 | 233篇 |
1980年 | 208篇 |
1979年 | 200篇 |
1978年 | 194篇 |
1977年 | 212篇 |
1976年 | 194篇 |
1974年 | 157篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
71.
72.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献
73.
74.
75.
76.
目的:通过对21例髋臼爆裂性骨折伴股骨头脱位的手术治疗,探讨处理此类损伤应注意的几个问题。方法:术前 X片及CT片明确骨折及脱位类型,采用患侧扩大的髂股入路或Langenbeck-Kocher入路,显露髂骨内外板及小骨盆内壁、髋臼前后柱,必要时显露坐骨大切迹,保持股骨头于脱位状态,直视下复位各骨折块尽量达到髓关节内软骨面光滑圆弧,在骨折复位状态下行内固定,之后使股骨头复位入髋臼,术后皮牵引,早期锻炼。结果:术后21例随访12~36个月, 骨折均愈合好,髋臼内壁形态光滑,元再脱位或创伤性关节炎症状出现。结论:髋臼爆裂性骨折伴股骨头脱位的病例,早期手术恢复髋臼内壁软骨面光滑圆弧可最大限度的恢复患肢功能,能有效地防止髓关节创伤性关节炎的发生,手术切口的选择是复位成功的关键,同时深静脉栓塞、坐骨神经的损伤及异位骨化的预防应予以重视。 相似文献
77.
78.
79.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
80.
高压氧综合治疗持续植物状态30例疗效分析 总被引:14,自引:0,他引:14
目的评估高压氧综合治疗持续植物状态的疗效和探讨最佳治疗方案。方法回顾性分析了1999年—2005年应用高压氧治疗的30例持续植物状态病例,主要分析了原发病因、高压氧治疗次数以及高压氧治疗时机与疗效的关系。结果脑外伤组显效率和好转率明显高于非脑外伤组(P<0.05),开始治疗时间≤30d组及31~60d组好转率明显高于≥61d组(P<0.05)。结论高压氧综合治疗对脑外伤所致持续植物状态患者60d以内开始行高压氧治疗的患者疗效较好。 相似文献